offers corrective and filling action to skin damages, caused by:
  *   the natural skin ageing process that leads to reduction of hydration, loss of elasticity and decline of collagen and elastin fibers
  *   Processes of skin tissue restoration in cases of scars due to superficial damages (e.g. acne or chickenpox scars)
Designed TO IMPROVE SKIN LAXITY of face, neck, and decolletage, it promotes the restoration of firmness, tone and elasticity of tissues in an authentic way.
Distinctive features of the product are:
High HA concentration (64mg/2ml), high manageability, extensive spreadability, low viscosity, no BDDE or other chemical agents, low inflammatory response.



Profhilo exclusively distributed by Marugagroup in Greece and Cyprus and trained by Marugagroup and Dermishellas. A unique stabilised injectable hyaluronic acid for treating skin laxity.
BDDE-free and with one of the highest concentrations of HA on the market (64 mg / 2 ml), it is not only boosting and hydrating the skin, but also remodels the ageing and sagging tissue.
Profhilo delivers great results as a treatment on its own or in combination with other aesthetics treatments currently on offer.


As a stabilised product Profhilo lasts in the skin around 28 days. During this time the stimulation of 4 different types of collagen and elastin takes place by slow release of HA.

The stimulation results in significant tissue improvement. Therefore we cannot say that Profhilo is a skin booster as it also has a significant tightening / lifting effect on the tissue.


There are many characteristics that make Profhilo unique from anything else available on the market right now. There is no BDDE content. It is thermally cross-linked generating stabilised hybrid co-operative complexes of H-HA and L-HA. Despite its high HA content, it has a low inflammatory profile coupled with pro-healing properties backed by clinical studies. To fully understand this new concept in anti-ageing medicine we have to take a look at the technology first.